Fundraising Fox

Stargazer Pharmaceuticals

Boston, US · Founded 2018 · Delaware corporation · 2 known investors

Biotech

Founders & leadership

GS
Gary SternbergExecutive

Board

IRIyona Rajkomar
Iyona RajkomarinBoard directorPartner at Pontifax Venture Capital
WHWende Hutton
Wende Huttonin𝕏Board directorGeneral Partner at Canaan Partners
RG
Richard GasterBoard director
NL
Nanna LuneborgBoard director
DC
Daniel CurranBoard director
JW
John WagnerBoard director

Investors · 2

Pontifax Venture CapitalHerzeliya · $6.3M – $128M
Canaan PartnersreportedStamford · $500K – $20Mvia Wende Hutton · board

Reported raises · per SEC filings

Form D private placements

$28.5M disclosed across 1 round · 2018

▶$28.5MraisedMay 2020 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Iyona RajkomarDirector
  • Wende HuttonDirector
  • Gary SternbergExecutive Officer, Director
  • Richard GasterDirector
  • Nanna LuneborgDirector
  • Daniel CurranDirector
  • John WagnerDirector
Offering amount
$62.2M
Amount sold
$28.5M
First sale
Apr 2018
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharmabarchart.com · Feb 2026Stargazer Pharmaceuticals Raises $57 Million for Rare Eye Disease Therapies - Global Genesglobalgenes.org · Nov 2020Stargazer Pharmaceuticals Initiates a Phase 2a Clinical Trial for its Stargardt Disease Drug — Foundation Fighting Blindnessfightingblindness.org · Nov 2020Stargazer Pharmaceuticals, Inc. Announces $57 Million Series A Financing and Initiation of a Phase 2a Clinical Study of STG-001 in Stargardt Disease Patients | Retinal Degeneration Fundretinaldegenerationfund.org · Nov 2020

Frequently asked questions

Who are Stargazer Pharmaceuticals's investors?
Stargazer Pharmaceuticals's investors include Pontifax Venture Capital, Canaan Partners.
How much funding has Stargazer Pharmaceuticals raised?
Stargazer Pharmaceuticals has disclosed $28.5M raised across 1 round.
Where is Stargazer Pharmaceuticals headquartered?
Stargazer Pharmaceuticals is headquartered in Boston, US.